Jyong Biotech (MENS)
Develops botanical drug candidates for urinary-system diseases.
Something off on this page? Send us feedback.
Develops plant-derived therapeutics for urinary-system diseases, led by botanical drug candidate Botreso and MCS-8. The pre-revenue company operates through a Cayman parent and Taiwan-based subsidiaries; its candidates remain investigational and unapproved.
Develops plant-derived therapeutics for urinary-system diseases through a Cayman parent and operating subsidiaries principally based in Taiwan. Its stated initial markets are the United States, European Union, and Asia. The pipeline is led by botanical drug candidate Botreso and MCS-8, while the underlying operating business traces to Health Ever Bio-Tech, founded in 2002.
Revenue has not been generated, and MCS-2 and MCS-8 remain investigational and unapproved in every jurisdiction. Progress therefore depends on clinical, regulatory, manufacturing, and financing milestones rather than sales of an approved product. Fu-Feng Kuo, who founded Health Ever Bio-Tech, remains chairwoman and CEO.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $1.2M · Total debt $18.5M · Total assets $20.8M · Shareholders' equity −$24.9M
- Revenue
- $0
- Operating income
- −$1.8M
- Net income
- −$3.4M
No dividends on record.
| Institutions17 holders · as of Mar 31, 2026 | 0.60% | 453.6K shares | |
| Otherremainder | 99.40% | 75.57M shares |
76.03M company shares as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
BlackRock, Inc.Institution | 0.34% | 258,760 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 0.08% | 64,232 | 13Fas of Mar 31, 2026 |
UBS Group AGInstitution | 0.05% | 37,363 | 13Fas of Mar 31, 2026 |
Millennium Management LLCInstitution | 0.02% | 14,590 | 13Fas of Mar 31, 2026 |
Vanguard Personalized Indexing Management, LLCInstitution | 0.02% | 13,927 | 13Fas of Mar 31, 2026 |
| See all 17 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Organon
Oral BPH therapy with finasteride and long-established labeling
- Eli Lilly
Once-daily oral tadalafil therapy for BPH symptoms
- Teleflex
Implant-based minimally invasive treatment for BPH/LUTS
- Boston Scientific
Water-vapor procedure that reduces BPH-related prostate tissue
- Johnson & Johnson
Oral IC therapy for bladder pain or discomfort
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Jyong Biotech | $2.24 | −1.32% | $171.1M | — | — | — | — |
| Organon | $13.76 | −0.15% | $3.62B | 17.9 | 3.9 | 0.6 | −2.3% |
| Eli Lilly | $1,165.80 | +0.55% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Teleflex | $140.89 | +0.03% | $6.24B | — | 15.3 | 2.4 | −27.0% |
| Boston Scientific | $48.52 | +0.30% | $71.90B | 19.7 | 14.6 | 3.4 | +7.5% |
| Johnson & Johnson | $275.19 | −0.02% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Median | 25.8 | 15.3 | 3.4 | +6.6% |